The effect of preoperative statin treatment on acute kidney injury in elderly patients undergoing valve replacement surgery

Eur J Clin Pharmacol. 2022 Mar;78(3):505-512. doi: 10.1007/s00228-021-03252-4. Epub 2021 Nov 23.

Abstract

Purposes: The effects of preoperative statin treatment on acute kidney injury (AKI) remain controversial, and current clinical evidence regarding statin use in the elderly undergoing valve replacement surgery (VRS) is insufficient. The present study aimed to investigate the association between preoperative statin treatment and AKI after VRS in the elderly.

Methods: Three thousand seven hundred ninety-one elderly patients (≥ 60 years) undergoing VRS were included in this study and divided into 2 groups, according to the receipt of statin treatment before the operation: statin users (n = 894) and non-users (n = 2897). We determined the associations between statin use, AKI, and other adverse events using a multivariate model and propensity score-matched analysis.

Results: After propensity score-matched analysis, there was no difference between statin users and non-users in regard to postoperative AKI (72.5% vs. 72.4%, p = 0.954), in-hospital death (5.7% vs. 5.1%, p = 0.650) and 1-year mortality (log-rank = 0, p = 0.986). The multivariate analysis showed that statin use was not an independent risk factor for postoperative AKI (OR = 0.97, 95% CI: 0.90-1.17, p = 0.733), in-hospital mortality (OR = 1.12, 95% CI: 0.75-1.68, p = 0.568), or 1-year mortality (HR = 0.95, 95% CI: 0.70-1.28, p = 0.715).

Conclusion: Preoperative statin treatment did not significantly affect the risk of AKI among elderly patients undergoing VRS.

Keywords: Acute kidney injury; Elderly patient; Prevention; Statin; Valve replacement surgery.

MeSH terms

  • Acute Kidney Injury / epidemiology*
  • Aged
  • Female
  • Heart Valve Prosthesis Implantation / adverse effects*
  • Hospital Mortality / trends
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
  • Male
  • Middle Aged
  • Postoperative Complications / epidemiology*
  • Risk Factors
  • Socioeconomic Factors

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors